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SUMMARY
In this study we have examined intracellular cytokines in peripheral blood mononuclear cells (PBMC)
of MS patients by flow cytometry (cytokine flow cytometry). MS progressive patients showed an
increased number of cells producing interferon-gamma (IFN-g) after activation with phorbol 12-
myristate 13-acetate and ionomycin, compared with patients with clinically inactive forms (P < 0001)
and with healthy controls (P ¼ 0001). These cells belonged to the CD4þ and CD8þ subsets in similar
proportions. Clinically inactive patients showed a lower level of cells producing IL-2 than controls
(P ¼ 0·03) and active MS patients (P ¼ 0·03). Most IL-2-producing cells were CD4þ lymphocytes,
although a small part of the IL-2 was also produced by CD8þ cells. The percentage of cells producing
simultaneously IL-2 and IFN-g was increased in active MS and they were mainly CD4þ lymphocytes.
No differences in the production of IL-4 were observed between groups. However, we found an
increased IL-10 production in clinically active MS patients (P ¼ 0·03). Treatment with IFN-b of active
MS patients showed lower levels of cytokines when compared with untreated MS patients. This
methodological approach could help in the follow up and therapeutic monitoring of MS patients.
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INTRODUCTION
MS is a T cell-mediated chronic inflammatory disease of the
central nervous system. The role of cytokines in the pathogenesis
of the disease has been extensively studied, although many ques-
tions remain unresolved [1–3]. In this sense, the measurement of
cytokine levels could be a useful marker of disease activity. Their
detection might have diagnostic and prognostic implications as
well as a putative value in monitoring clinical trials, possibly
leading to new therapeutic strategies. Measurements of different
cytokines in biological fluids from MS patients performed in
previous studies have given conflicting results. Differences in the
methodology used, specimen sampling or handling, or in patient
selection criteria, can partly explain the discrepant findings [4,5].
The demonstration of cytokines at the single-cell level could
help to solve the above mentioned problems [6]. The detection of
intracellular cytokines by the use of anti-cytokine MoAbs and flow
cytometry recently introduced by Jung et al. [7] (‘cytokine flow
cytometry’ [8]), adds the possibility of defining the T cell sub-
populations involved in the production of these cytokines as well
as of assessing the simultaneous production of different cytokines
by the same cell [9].
In this study we have developed this method in order to obtain
rapid and accurate information about the immunological situation
of MS patients which could help in their follow up and therapeutic
monitoring.
We report an increase of proinflammatory cytokines (inter-
feron-gamma (IFN-g)) in clinically active forms of MS compared
with inactive forms and with healthy controls, this increase being
due both to CD4þ and CD8þ T cell subpopulations and disappear-
ing after treatment with IFN-b. The assessment of immunoregula-
tory cytokines (IL-4 and IL-10) in the same patients allowed us to
draw a more complete picture of their immunological situation.
MATERIAL AND METHODS
Patients
Twenty-seven patients with MS were studied. Thirteen (eight
female, mean age 42 years, range 20–67 years) had chronic
active progressive forms and 14 (10 female, mean age 38 years,
range 20–56 years) had relapsing-remitting clinically stable forms
of the disease. All these patients satisfied the diagnostic criteria of
Poser et al. (1983). They were under no treatment at the time of
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study. The control group consisted of 14 healthy subjects (10
female, mean age 40 years, range 19–65 years) who were age- and
sex-matched to the patients.
To determine whether the treatment could influence intracel-
lular cytokine production, we also studied a group of 16 patients
(eight active progressive forms, mean age 42 years, range 32–
52 years, and eight relapsing-remitting stable forms, mean age
33 years, range 22–48 years) treated with IFN-b (Betaseron) at a
dose of 8 · 106 U subcutaneously every other day.
Peripheral blood mononuclear cell isolation and processing
Peripheral blood mononuclear cells (PBMC) were isolated from
heparinized venous blood by density gradient centrifugation on
Ficoll–Hypaque. Blood sampling was done early in the morning
and managed blind with respect to the clinical status of the patient.
PBMC at the interface were collected and washed three times with
PBS. After washing, the cells were adjusted to a concentration of
2 · 106 cells/ml in RPMI 1640 supplemented with 10% heat-
inactivated fetal calf serum (FCS) and 2 mM L-glutamine and
cells were stimulated for cytokine production for 4 h at 378C with
10 ng/ml phorbol 12-myristate 13-acetate in combination with
1 mg/ml ionomycin (PMA þ I; (Sigma, St Louis, MO) in the presence
of 10 mg/ml of brefeldin A (Sigma), which disrupts intracellular
protein transport and causes cytokines to accumulate in the Golgi
apparatus, yielding an enhanced cytokine signal that can be
detected by flow cytometry. Preliminary experiments indicated
that maximal accumulation of intracellular cytokine occurred after
4 h of PMA þ I stimulation in the presence of brefeldin A.
To determine the T cell subpopulation responsible for the
cytokine production, a two- or three-colour staining technique
was performed. The activated cells were pooled and washed in
PBS with bovine serum albumin (BSA; 0·5%) and sodium azide
(0·01%) (PBS–BSA–azide). Then 100 ml of the cellular suspen-
sion were stained with a fluorochrome-conjugated antibody
specific for a cell surface antigen (CD4 or CD8 PerCP; Becton
Dickinson, San Jose´, CA) for 15 min at room temperature. There-
after, cells were fixed (Fix and Perm; Caltag, San Francisco, CA)
according to the manufacturer’s instructions. After washing in
PBS–BSA–azide, cells were resuspended in 100 ml of PBS and an
optimal dose of a fluorochrome-conjugated antibody for intra-
cellular staining (double-labelling was performed with anti-human
IL-2–FITC–anti-human IFN-g–PE, and anti-human IFN-g–FITC–
anti-human IL-4–PE; Becton Dickinson; for single-labelling, anti-
human IL-4–FITC and anti-human IL-10–FITC (Caltag, Ingelheim,
Germany) were used) was added, together with 100 ml of permea-
bilizing solution (Fix and Perm; Caltag). Cells were incubated for
30 min at 48C and washed once in PBS–BSA–azide. The super-
natants were aspirated and the pellets resuspended in 500 ml of
0·5% paraformaldehyde to be analysed by flow cytometry.
As controls we included cells labelled with isotype-matched
irrelevant MoAbs and non-activated lymphocytes labelled with
anti-cytokine antibodies.
Acquisition and analysis of flow cytometry data
Samples were analysed on a FACSORT flow cytometer (Becton
Dickinson) using Cell Quest software (Becton Dickinson). Ten
thousand events per lymphocyte population were acquired and
analysed. Analysis gates were set on lymphocytes according to
forward and side scatter properties. Results are expressed as the
percentage of cytokine-producing cells in a population of specified
cells (see Results).
Statistical analysis
Differences between groups were tested with the Mann–Whitney
non-parametric U-test when data were not normally distributed,
and with Student’s paired t-test when the data were normally
distributed. Reported P values are two-tailed and P < 0·05 was
considered statistically significant.
RESULTS
The production of cytokines by unstimulated or PMA þ I-activated
lymphocytes was evaluated in 13 chronic active progressive MS
patients, 14 stable relapsing-remitting MS patients and 14 controls.
Results are expressed as the percentage of cytokine-producing
cells in the total lymphocyte population.
Spontaneous cytokine production by PBMC
Freshly isolated lymphocytes from MS patients and healthy con-
trols did not constitutively express proinflammatory cytokines (IL-
2, IFN-g) (Table 1). No differences were found between the three
groups.
Concerning immunoregulatory cytokines (IL-4, IL-10)
(Table 1), IL-4 was not detected in unstimulated cells in any of
the three groups. However, both in control and MS patients we
detected spontaneous IL-10 production. Moreover, the percentage
of cells that spontaneously produced IL-10 was significantly higher
in active forms of MS than in inactive forms of the disease (12·59%
versus 6·77%; P ¼ 0·03). No differences were found between
controls and MS patients.
Cytokine production after stimulation with PMA þ I
After activation with PMA þ I (Table 2), the percentage of IL-2-
secreting cells in inactive MS patients was significantly decreased
when compared with active MS patients (17·24% versus 26·75%;
P ¼ 0·03) and with healthy controls (17·24% versus 25·08%;
P ¼ 0·03). No differences were found between active MS patients
and healthy controls.
Concerning IFN-g-secreting cells (Table 2), we found a higher
percentage in active MS patients than in inactive patients (19·10%
versus 11·51%; P< 0001) and healthy controls (19·10% versus
14·57%; P ¼ 0·001).
When we studied the simultaneous expression of IFN-g and IL-
2 in peripheral blood lymphocytes, we found that active MS
patients showed a higher percentage of double-positive cells than
inactive MS patients (7·87% versus 4·28%; P ¼ 0·007). Controls
(5·62% 6 1·52%) were not different from MS patients.
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Table 1. Percentage (mean 6 s.d.) of non-activated peripheral blood lym-
phocytes producing cytokines in non-treated clinically different groups of
MS patients and controls.
Controls Inactive MS Active MS
(n ¼ 14) (n ¼ 14) (n ¼ 13)
IL-2 0·64 6 0·46 0·77 6 0·29 0·51 6 0·37
IFN-g 0·67 6 0·46 0·78 6 0·60 0·59 6 0·40
IL-4 0·72 6 0·47 1·54 6 2·31 1·06 6 1·01
IL-10 6·78 6 5·17 6·77 6 7·84* 12·59 6 9·94*
*P ¼ 0·03.
No differences were found in the production of IL-4 or IL-10
between groups.
Phenotypic characterization of the cytokine-producing
subpopulation
To determine the lymphocyte subpopulation responsible for the
production of cytokines, we performed three-colour flow cyto-
metry by staining lymphocytes with anti-CD4 or anti-CD8 and two
anti-cytokine antibodies with different fluorochromes.
Our results show that IL-2 was mainly produced by CD4þ
cells, although CD8þ lymphocytes contributed in some proportion
(Fig. 1). Both CD4þ IL-2þ and CD8þ IL-2þ subsets were
decreased in inactive MS patients with respect to active patients
(P ¼ 0·05 and P ¼ 0·01, respectively) and controls (P ¼ 0·05 and
P ¼ 0·01, respectively).
By contrast, IFN-g was produced in similar proportions by
CD4þ and CD8þ T cells (Fig. 2). Both CD4þ IFN-gþ and
CD8þ IFN-gþ subsets were increased in active MS patients com-
pared with inactive patients (P ¼ 0·001 and P < 0·001, respec-
tively). When compared with controls, active MS patients
showed higher values of the CD4þ IFN-gþ subset (P ¼ 0·01) and
inactive MS patients show a decrease in the CD8þ IFN-gþ T cell
subset (P ¼ 0·01).
The effect of treatment with IFN-b on the production of cytokines
The effect of the treatment of MS patients (chronic progressive
forms, n ¼ 8) with IFN-b was evaluated in terms of the production
of intracellular cytokines by PBMC.
We found that the levels of proinflammatory cytokines, namely
IL-2 (26·75% versus 17·95%; P ¼ 0·003) and IFN-g (19·10% versus
11·98%; P ¼ 0·002), were lower in active MS patients under IFN-b
treatment compared with untreated patients. However, the percen-
tage of IL-4- or IL-10-producing cells was not altered by this type
of treatment (Table 2).
DISCUSSION
Quantification of intracellular cytokines at the single-cell level
constitutes a valuable approach to evaluate the immunological
status of patients with MS. We have shown in this study a good
correlation between the cytokine profile and the clinical activity of
patients.
In order to detect cytokine production we induced non-specific
lymphocyte activation. As few resting lymphocytes express cyto-
kines, we took the fact that only activated lymphocytes express
cytokines as evidence of the specificity of the labelling. We used
PMA þ I to activate PBMC of MS patients (activation was con-
firmed by induction of CD69, data not shown). We decided to use
the same activator (PMA þ I) for the induction of all the cytokines
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Table 2. Percentage (mean 6 s.d.) of phorbol 12-myristate 13-acetate þ ionomycin (PMA þ I)-activated peripheral blood lymphocytes cytokine-producing
cells in non-treated and IFN-b-treated clinically different groups of MS patients and controls.
Controls Non-treated inactive MS Non-treated active MS IFN-b-treated active MS
(n ¼ 14) (n ¼ 14) (n ¼ 13) (n ¼ 8)
IL-2 25·08 6 5·68† 17·24 6 11·28*† 26·75 6 10·41*††† 17·95 6 7·65†††
IFN-g 14·57 6 3·79** 11·51 6 4·61†† 19·10 6 5·54**††*** 11·98 6 3·79***
IL-4 2·78 6 1·92 2·56 6 1·68 1·72 6 1·09 1·97 6 1·29
IL-10 2·51 6 1·92 2·38 6 1·58 3·82 6 3·09 3·29 6 3·80
*†P ¼ 0·03; **P ¼ 0·001; ***P ¼ 0·002; ††P< 0·001; †††P ¼ 0·003.
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Fig. 1. IL-2 production by peripheral blood phorbol 12-myristate 13-
acetate þ ionomycin (PMA þ I)-activated lymphocytes in CD4 and CD8
T cells in non-treated clinically different groups of MS patients and
controls. W, CD8þ IL-2þ; B, CD4þ IL-2þ. *,**P ¼ 0·05; †,††P ¼ 0·01.
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Fig. 2. IFN-g production by peripheral blood phorbol 12-myristate
13-acetate þ ionomycin (PMA þ I)-activated lymphocytes in CD4
and CD8 T cells in non-treated clinically different groups of
MS patients and controls. X, CD8þ IFN-gþ; A, CD4þ IFN-gþ.
*P ¼ 0·01; **P < 0·001; †P ¼ 0·01; ††P ¼ 0·001.
for more general applicability in clinical practice. This type of
activation has been criticised as not being a physiologic stimulus.
However, different studies show that the cytokine phenotypes
derived upon PMA þ I activation represent the physiologic poten-
tial of cellular cytokine production [8,10,11].
With this approach we have shown that clinically active
patients show a higher percentage of IFN-g-producing lympho-
cytes after stimulation with PMA þ I than healthy controls or
inactive MS patients. The quantification of IFN-g production by
PBMC of MS patients has offered conflicting results when using
ELISA for detection of this cytokine in plasma [12,13], cerebro-
spinal fluid (CSF) [14] or culture supernatants [15–20]. In these
cases, no correlation with clinical activity or magnetic resonance
imaging (MRI) findings was found. Only investigators using
detection of cytokine mRNA [21,22] showed a good correlation
with disease activity, as supported by our results.
Our study shows that the level of production of IL-2 is lower in
inactive forms of MS (remission) than in active MS, in agreement
with other published data [23–25]. Importantly, however, as
previously noted by Merrill et al. [26], the production of IL-2 is
lower in remission than in controls, probably indicating an
immunosuppressed state after the acute relapse recovery.
IL-10 was the only cytokine which we could detect in resting
lymphocytes, especially in patients with active MS. An immuno-
suppressive function has been postulated for IL-10 in MS, as it is
present mainly in non-active MS forms [27,28]. Activated lym-
phocytes produced less IL-10 than resting cells, a fact which can be
attributed to the stimulus used (PMA þ I). It has been described
that the calcium ionophore A23187 inhibits IL-10 production
induced by PMA [29].
We detected very small amounts of IL-4, with no differences
between groups. Published data about IL-4 levels in MS patients
are not conclusive [21,25,30]. In some cases a small increment has
been demonstrated in inactive forms by the use of highly sensitive
techniques. It is probable that our method lacked the sensitivity to
detect these subtle changes.
Our results suggest that the balance between the different
cytokines is more important than the absolute levels of each.
Thus, we have shown that that clinically active forms of the
disease present the highest levels of proinflammatory cytokines,
such as IFN-g, and at the same time the highest amounts of IL-10,
which has been implicated as an immunosuppressive cytokine
[27,28]. Perhaps the latter represents an early or weak attempt to
regulate an overactive inflammatory process. Indeed, Diab et al.
found IL-10-producing cells in experimental allergic encephalo-
myelitis (EAE) lesions at the end of the acute phase [31]. In
remission, on the other hand, IFN-g is below normal levels, as
lower levels of IL-10 are sufficient to maintain a non-inflammatory
situation without clinical activity of the disease.
The simultaneous detection of cytokines and cell surface
antigens allowed us to define the pattern of cytokines in different
T cell subpopulations. While IL-2 is produced almost exclusively
by CD4þ cells, CD8þ lymphocytes contribute almost as much
IFN-g as the CD4 in active MS (Tc1). Some evidence points to a
possible role of CD8þ T cells in the pathogenesis of MS: (i) its
presence in central nervous system (CNS) lesions of MS; (ii)
they are the only T cells able to recognize antigens locally in
CNS; and (iii) an immunoregulatory effect on the course of
experimental EAE has been attributed to these cells [32]. Our
data could add new evidence to the pathogenic role of CD8þ
cells in MS patients.
PBMC activation with PMA þ I led to the production either of
IL-2 or of IFN-g. Only a small percentage of cells produced both
cytokines simultaneously, as already reported [7,9]. This modest
percentage of mainly CD4þ cells was nevertheless higher in
clinically active MS. These data are in concordance with the Th1
pattern of cytokines described in MS patients [33,34], including the
study of T cell clones derived from MS patients in different clinical
situations [35].
Finally, we found lower frequencies of IL-2- and IFN-g-
producing cells in patients with progressive MS who were treated
with IFN-b than in untreated cases. This type of treatment is being
used in the relapsing-remitting form of the disease, although some
clinical trials are trying to extend this application to other clinical
forms [36]. This result supports the use of IFN-b in progressive
forms of the disease, given the biological response to the treatment
we have observed in these patients.
In conclusion, we believe that this method of cytokine detec-
tion could help in the follow up of MS patients, offering valuable
information about their immunological situation.
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